30 results on '"Rivoli, Giulia"'
Search Results
2. Amino acid depletion triggered by ʟ-asparaginase sensitizes MM cells to carfilzomib by inducing mitochondria ROS-mediated cell death
3. Cardiac effects of deferasirox in transfusion‐dependent patients with myelodysplastic syndromes: TELESTO study.
4. Histopathological Markers for Target Therapies in Primary Cutaneous Lymphomas
5. AML-394 Tagraxofusp in Blastic Plasmacytoid Dendritic Cell Neoplasm With/Without Central Nervous System Involvement and Intrathecal Chemotherapy as Primary Treatment or Prophylaxis: An Italian Experience
6. Blastic plasmacytoid dendritic cell neoplasm: a short review and update
7. Blastic plasmacytoid dendritic cell neoplasm: a short review and update.
8. Real-World Validation of Molecular International Prognostic Scoring System for Myelodysplastic Syndromes
9. Real-World Validation of Molecular International Prognostic Scoring System for Myelodysplastic Syndromes
10. Good tolerability of high dose colistin-based therapy in patients with haematological malignancies
11. Real-World Validation of Molecular International Prognostic Scoring System (IPSS-M) for Myelodysplastic Syndromes
12. Efficacy and Safety of Luspatercept in Adult Patients with Transfusion-Dependent Anemia Due to Very Low, Low and Intermediate Risk Myelodysplastic Syndromes (MDS) with Ring Sideroblasts, Who Had an Unsatisfactory Response to or Are Ineligible for Erythropoietin-Based Therapy: A Retrospective Multicenter Study By Fondazione Italiana Sindromi Mielodisplastiche (FiSiM ETS)
13. Tagraxofusp Administered Concomitantly with Intrathecal Chemotherapy in Patients with BPDCN who Either Have or are Considered High-risk to Develop CNS Disease is a Safe and Effective Treatment Strategy: An Italian Multicenter Experience
14. Poster: AML-394 Tagraxofusp in Blastic Plasmacytoid Dendritic Cell Neoplasm With/Without Central Nervous System Involvement and Intrathecal Chemotherapy as Primary Treatment or Prophylaxis: An Italian Experience
15. Real-World Efficacy and Safety of Luspatercept in Adult Patients with Transfusion-Dependent Anaemia Due to Lower-Risk Myelodysplastic Syndromes with Ring Sideroblasts (MDS-RS), Who Had an Unsatisfactory Response to or are Ineligible for Erythropoiesis Stimulating Agents: A Retrospective, Multicenter, Cohort Study
16. Hepatosplenic T-cell lymphoma with aberrant expression of serum β-HCG: a case report
17. Clinical and Genomic-Based Decision Support System to Define the Optimal Timing of Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Myelodysplastic Syndromes (MDS)
18. Tyrosine Kinase Inhibitor (TKI) Discontinuation in Non-Allografted Ph+ Acute Lymphoblastic Leukemia Patients, a Campus ALL Real-Life Study
19. Molecular Classification of Chronic Myelomonocytic Leukemia: Results of the Analysis of an International Cohort of 2,471 Patients
20. Erwinia Chrysantemi-Derived L-Asparaginase Strongly Enhances Proteasome Inhibitors Activity By Deregulating Cell Metabolic Programs
21. Finding the Best Therapy for Elderly Frail AML Patients: A Retrospective Comparison of 5-Azacytidine and Intensive Approach
22. CD38 Deregulation As Strategy to Make Multiple Myeloma Cells More Sensitive to NAD+ Depleting Agents
23. High Prognostic Value of a 3-Genes Molecular Score in Non-High Risk Acute Promyelocytic Leukemia Treated with AIDA 2000 Protocol: A Retrospective Study from a Regional Register
24. Comparison of the Efficacy and Feasibility of R-CODOX-M/IVAC-R Versus Conventional R-CHOP As First Line Regimen for High Risk Diffuse Large B-Cell Lymphoma
25. Glutamine-Dependence Targeting By Asparaginase Significantly Increases Anti-Myeloma Activity of Proteasome Inhibitors
26. Lenalidomide Maintenance with or without Prednisone in Newly Diagnosed Myeloma Patients: A Pooled Analysis.
27. Comparison of the Efficacy and Feasibility of R-CODOX-M/IVAC-R Versus Conventional R-CHOP As First Line Regimen for High Risk Diffuse Large B-Cell Lymphoma
28. Glutamine-Dependence Targeting By Asparaginase Significantly Increases Anti-Myeloma Activity of Proteasome Inhibitors
29. Methodology and clinical utility of longitudinal UBA1 tracking in VEXAS syndrome.
30. Real-world efficacy and safety of luspatercept and predictive factors of response in patients with lower risk myelodysplastic syndromes with ring sideroblasts.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.